



Precision oncology

Oncomine Dx Target Test—the right choice for your patients

Analyze all key biomarkers for *EGFR*, *ALK*, *BRAF*, and *ROS1* kinase inhibitors, and many more currently in clinical trials, from one sample, in one report, in 4 days

The Ion Torrent™ Oncomine™ Dx Target Test is the first CE-IVD solid-tumor biomarker test, based on targeted next-generation sequencing (NGS), which detects key biomarkers that are relevant to currently approved and investigative targeted therapies in solid tumors.

The only solid tumor biomarker test, which can:

- Detect 46 cancer driver gene variants, including *EGFR* mutations (including L858R, T790M, and exon 19 deletions); *BRAF*, *KRAS*, *ERBB2*, and *MET* exon 14 skipping mutations; and *ALK*, *ROS1*, *RET*, and *NTRK1/2/3* fusions
- Deliver an all-in-one report to support treatment decisions—including multiple drug indication options—enabling time and cost savings
- Deliver results even for challenging small samples, meaning more patients can potentially access targeted therapies
- Enable faster treatment decisions by generating laboratory results in 4 days




Figure 1: Oncomine Dx Target Test delivers key biomarkers associated with targeted therapies from one sample, in one test workflow, and one report.

ThermoFisher
SCIENTIFIC

NSCLC	Colon	Melanoma	Ovarian	Gastric
AKT1	ALK	ALK	AKT1	ALK
ALK	BRAF	BRAF	BRAF	EGFR
BRAF	EGFR	GNA11	FGFR3	ERBB2
DDR2	ERBB2	GNAQ	GNA11	ERBB3
EGFR	ERBB3	HRAS	GNAQ	FGFR2
ERBB2	HRAS	KIT	HRAS	FGFR3
ERBB3	IDH1	KRAS	KRAS	MET
FGFR2	KRAS	MAP2K1	MAP2K1	NTRK1
FGFR3	NRAS	NRAS	NRAS	NTRK2
GNA11	NTRK1	NTRK1	NTRK1	NTRK3
GNAQ	NTRK2	NTRK2	NTRK2	PIK3CA
HRAS	NTRK3	NTRK3	NTRK3	
KIT	PIK3CA	RAF1		
KRAS	ROS1	ROS1		
MAP2K1				
MET				
MTOR				
NRAS				
NTRK1				
NTRK2				
NTRK3				
PDGFRA				
PIK3CA				
RAF1				
RET				
ROS1				

Figure 2. Examples of genes with cancer driver variants associated with different tumor types.

All genes included in the Oncomine Dx Target Test			
DNA panel, hotspot genes	AKT1	FGFR2	MAP2K1
	ALK	FGFR3	MAP2K2
	AR	GNA11	MET
	BRAF	GNAQ	MTOR
	CDK4	HRAS	NRAS
	CTNNB1	IDH1	PDGFRA
	DDR2	IDH2	PIK3CA
	EGFR	JAK1	RAF1
	ERBB2	JAK2	RET
	ERBB3	JAK3	ROS1
	ERBB4	KIT	SMO
	ESR1	KRAS	
	RNA panel, fusion drivers	ABL1	ETV4
ALK		ETV5	NTRK3
AXL		FGFR1	PDGFRA
BRAF		FGFR2	PPARG
ERBB2		FGFR3	RAF1
ERG		MET	RET
ETV1		NTRK1	ROS1

Figure 3. All genes covered by the Oncomine Dx Target Test.

With the Oncomine Dx Target Test, you and your care team are ready for the future




Figure 4. 73% of oncology drugs in development are personalized medicines.*

In oncology, most of the drugs in development are precision medicines associated with molecular testing. As such, fast, broad, and accessible genomic profiling is becoming one of the key factors to ensure patients' access to the therapies they could potentially benefit from.

The 46 gene targets included in the Oncomine Dx Target Test are cancer driver genes which, based on their role in cancer pathogenesis, have the potential to be therapy targets. Many of them are already targets of approved or investigational therapies for solid tumors.

The Oncomine Dx Target Test can help ensure that your lab will be ready to provide you with all of these biomarkers as they become relevant, without the need for additional resources to implement new and emerging tests.



* The Personalized Medicine Report by PMC (Personalized Medicine Coalition, 2017).